C
Chiaki Kagebayashi
Researcher at Wako Pure Chemical Industries, Ltd
Publications - 11
Citations - 2279
Chiaki Kagebayashi is an academic researcher from Wako Pure Chemical Industries, Ltd. The author has contributed to research in topics: Hepatocellular carcinoma & Chronic liver disease. The author has an hindex of 8, co-authored 11 publications receiving 1548 citations. Previous affiliations of Chiaki Kagebayashi include Osaka University.
Papers
More filters
Journal ArticleDOI
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
Philip J. Johnson,Sarah Berhane,Chiaki Kagebayashi,Shinji Satomura,M Teng,Helen L. Reeves,James O'Beirne,Richard Fox,Anna Skowronska,D. Palmer,Winnie Yeo,Frankie Mo,Paul B.S. Lai,Mercedes Iñarrairaegui,Stephen L. Chan,Bruno Sangro,Rebecca A. Miksad,Toshifumi Tada,Takashi Kumada,Hidenori Toyoda +19 more
TL;DR: The ALBI grade offers a simple, evidence-based, objective, and discriminatory method of assessing liver function in HCC that has been extensively tested in an international setting and eliminates the need for subjective variables such as ascites and encephalopathy, a requirement in the conventional C-P grade.
Journal ArticleDOI
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients
Sarah Berhane,Hidenori Toyoda,Toshifumi Tada,Takashi Kumada,Chiaki Kagebayashi,Shinji Satomura,Nora Schweitzer,Arndt Vogel,Michael P. Manns,Julia Benckert,Thomas Berg,Maria Ebker,Jan Best,Alexander Dechêne,Guido Gerken,Joerg F. Schlaak,Arndt Weinmann,Marcus A. Wörns,Peter R. Galle,Winnie Yeo,Frankie Mo,Stephen L. Chan,Helen L. Reeves,Trevor Cox,Philip J. Johnson,Philip J. Johnson +25 more
TL;DR: The performance of the GALAD and BALAD-2 models for the diagnosis of HCC and predicting patient survival, respectively are validated in an international cohort of patients and might be used in HCC surveillance and determination of patient prognosis.
Journal ArticleDOI
The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers
Philip J. Johnson,Sarah Pirrie,Trevor Cox,Sarah Berhane,M Teng,Daniel H. Palmer,Janet Morse,Diana Hull,G.L. Patman,Chiaki Kagebayashi,Syed A. Hussain,Janine Graham,Helen L. Reeves,Shinji Satomura +13 more
TL;DR: Evidence is provided that an entirely objective serum biomarker–based model may facilitate the detection and diagnosis of hepatocellular carcinoma and form the basis for a prospective study comparing this approach with the standard radiological approaches.
Journal ArticleDOI
Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis.
Chiaki Kagebayashi,Isao Yamaguchi,Ayumi Akinaga,Hiromichi Kitano,Kazunori Yokoyama,Masahiro Satomura,Tatsuo Kurosawa,Mitsuo Watanabe,Tomohisa Kawabata,Chang William,Chen Li,Luc Bousse,Henry G. Wada,Shinji Satomura +13 more
TL;DR: Good correlation of test results for 68 patient serum samples with a commercially available reference method (LiBASys assay for AFP-L3%) was obtained, with r(2)=0.981 and slope=1.03.
Journal ArticleDOI
High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma
Takashi Kumada,Hidenori Toyoda,Toshifumi Tada,Seiki Kiriyama,Makoto Tanikawa,Yasuhiro Hisanaga,Akira Kanamori,Junko Tanaka,Chiaki Kagebayashi,Shinji Satomura +9 more
TL;DR: Elevation of hs-AFP-L3 was early predictive of development of HCC even at low AFP levels and in absence of ultrasound findings of suspicious HCC, and should be added to surveillance programs with US because elevated hs -AFP- L3 may be a trigger to perform enhanced imaging modalities for confirmation of H CC.